|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Solution structure of the tenth complement type repeat of human megalin== | | ==Solution structure of the tenth complement type repeat of human megalin== |
| - | <StructureSection load='2m0p' size='340' side='right'caption='[[2m0p]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | + | <StructureSection load='2m0p' size='340' side='right'caption='[[2m0p]]' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[2m0p]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2M0P OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2M0P FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[2m0p]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2M0P OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2M0P FirstGlance]. <br> |
| | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr> | | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[2i1p|2i1p]], [[2fyj|2fyj]]</div></td></tr> | |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">LRP2 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | |
| | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2m0p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2m0p OCA], [https://pdbe.org/2m0p PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2m0p RCSB], [https://www.ebi.ac.uk/pdbsum/2m0p PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2m0p ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2m0p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2m0p OCA], [https://pdbe.org/2m0p PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2m0p RCSB], [https://www.ebi.ac.uk/pdbsum/2m0p PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2m0p ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Disease == | | == Disease == |
| - | [[https://www.uniprot.org/uniprot/LRP2_HUMAN LRP2_HUMAN]] Donnai-Barrow syndrome. Donnai-Barrow syndrome (DBS) [MIM:[https://omim.org/entry/222448 222448]]: Rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g., agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Note=The disease is caused by mutations affecting the gene represented in this entry.<ref>PMID:17632512</ref>
| + | [https://www.uniprot.org/uniprot/LRP2_HUMAN LRP2_HUMAN] Donnai-Barrow syndrome. Donnai-Barrow syndrome (DBS) [MIM:[https://omim.org/entry/222448 222448]: Rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g., agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Note=The disease is caused by mutations affecting the gene represented in this entry.<ref>PMID:17632512</ref> |
| | == Function == | | == Function == |
| - | [[https://www.uniprot.org/uniprot/LRP2_HUMAN LRP2_HUMAN]] Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.
| + | [https://www.uniprot.org/uniprot/LRP2_HUMAN LRP2_HUMAN] Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 26: |
Line 24: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Dagil, R]] | + | [[Category: Dagil R]] |
| - | [[Category: Kragelund, B]] | + | [[Category: Kragelund B]] |
| - | [[Category: Complement type repeat]]
| + | |
| - | [[Category: Ldl receptor family]]
| + | |
| - | [[Category: Lipid binding protein]]
| + | |
| - | [[Category: Lrp2]]
| + | |
| - | [[Category: Megalin]]
| + | |
| - | [[Category: Receptor]]
| + | |
| Structural highlights
Disease
LRP2_HUMAN Donnai-Barrow syndrome. Donnai-Barrow syndrome (DBS) [MIM:222448: Rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g., agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Note=The disease is caused by mutations affecting the gene represented in this entry.[1]
Function
LRP2_HUMAN Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.
Publication Abstract from PubMed
is an aminoglycoside widely used in treatments of, in particular, enterococcal, mycobacterial and severe gram-negative bacterial infections. Large doses of gentamicin cause nephrotoxicity and ototoxicity, entering the cell via the receptor megalin. Until now, no structural information has been available to describe the interaction with gentamicin in atomic detail, and neither have any three-dimensional structures of domains from the human megalin receptor been solved. To address this gap in our knowledge, we have solved the NMR structure of the tenth complement type repeat of human megalin and investigated its interaction with gentamicin. Using NMR titration data in HADDOCK we have generated a three-dimensional model describing the complex between megalin and gentamicin. Gentamicin binds to megalin with low affinity and exploits the common ligand binding motif previously described (Jensen et al. (2006) J Mol Biol 362, 700-716) utilizing the indole side chain of Trp1126 and the negatively charged residues Asp1129, Asp1131 and Asp1133. Binding to megalin is highly similar to gentamicin binding to calreticulin. We discuss the impact of this novel insight for the future structure-based design of gentamicin antagonists.
Gentamicin Binds to Megalin as a Competitive Inhibitor Using the Common Ligand Binding Motif of Complement Type Repeats.,Dagil R, O'Shea C, Nykjaer A, Bonvin AM, Kragelund BB J Biol Chem. 2012 Dec 27. PMID:23275343[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, Bieth E, Chassaing N, Lacombe D, Devriendt K, Teebi A, Loscertales M, Robson C, Liu T, MacLaughlin DT, Noonan KM, Russell MK, Walsh CA, Donahoe PK, Pober BR. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet. 2007 Aug;39(8):957-9. Epub 2007 Jul 15. PMID:17632512 doi:10.1038/ng2063
- ↑ Dagil R, O'Shea C, Nykjaer A, Bonvin AM, Kragelund BB. Gentamicin Binds to Megalin as a Competitive Inhibitor Using the Common Ligand Binding Motif of Complement Type Repeats. J Biol Chem. 2012 Dec 27. PMID:23275343 doi:10.1074/jbc.M112.434159
|
